PlainPatent
USPTO 2015–2025 USPTO PatentsView US Corporation

Exploramed NC7, Inc.

USPTO PatentsView assignee record - 26 granted patents across 7 technology areas, recorded in grant years 2017–2020. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61M (DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY ; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY ; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR).

Explore the portfolio See the ranking
26
Total patents granted
7
CPC technology areas
12.0
Avg claims per patent
-27%
5-year grant velocity

The verdict

According to USPTO PatentsView, Exploramed ranks #11,644 of 50,000 tracked US assignees by granted-patent volume, with 26 patents across 7 technology areas.

#11,644
of 50,000 US assignees by volume
Top 74%
by Innovation Score (28.0/100)
12.0
avg claims per patent
-27%
grant velocity, last 5 yrs

Portfolio overview

Exploramed NC7, Inc. has been granted 26 US utility patents between 2017 and 2020, placing Exploramed NC7, Inc. at #11,644 of 50,000 across all assignees tracked by PlainPatent. This portfolio spans 7 distinct Cooperative Patent Classification (CPC) subclasses, averaging 12.0 claims per patent with primary concentration in A61M (DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY ; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY ; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR). As a US Corporation, Exploramed NC7, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Exploramed sits between Endotronix, Inc. (26 patents, rank #11,640) and First American Financial Corporation (26 patents, rank #11,648) - the closest US assignees by grant volume. The composite Innovation Score of 28.0/100 blends portfolio volume, grant velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Grant cadence records the difference between two grant-year windows. Between 2020 and 2024 the company received 11 grants, compared with 15 in the 2015–2019 window, a -27% shift in five-year grant velocity. Both windows cover five complete grant years; the latest PatentsView year is a partial release and is excluded from this comparison, though it still appears in the yearly table and chart below. Grant timing can lag the related application by years, so this comparison does not establish current R&D spending, strategic intent, or a company’s application activity. The US Corporation classification provides context for the assignee record, not a conclusion about its business strategy.

Claim depth and technology breadth describe this aggregate record. Exploramed NC7, Inc.'s 12.0 average claims per patent is an average count, not a measure of claim scope, legal strength, enforceability, or design-around risk. The record spans 7 CPC subclasses. Combined with portfolio volume, these figures let readers compare the documented grant records of assignees in similar technology classes.

Who files at Exploramed's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Exploramed holds 26 patents at rank #11,644, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Exploramed

By rank, the assignees closest to #11,644 in granted patent volume.

Leaders in A61M (Devices FOR Introducing Media INTO)

Other assignees with the most granted patents in Exploramed's primary technology class.

Exploramed's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

28 Top 74% higher than 26% of 50,000 US assignees

0–10: 687 US assignees (1%). Below this entry. 10–20: 2,527 US assignees (5%). Below this entry. 20–30: 13,162 US assignees (26%). This entry sits in this band. 30–40: 15,294 US assignees (31%). Above this entry. 40–50: 11,491 US assignees (23%). Above this entry. 50–60: 5,058 US assignees (10%). Above this entry. 60–70: 1,537 US assignees (3%). Above this entry. 70–80: 234 US assignees (0%). Above this entry. 80–90: 10 US assignees (0%). Above this entry. 90–100: 0 US assignees (0%). Above this entry. This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

024681012 2017201820192020 11
USPTO utility patent grants by year · 2017–2020

Grants by year

Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.

View data table
Exploramed NC7, Inc. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2017 2 7.7%
2018 6 23.1%
2019 7 26.9%
2020 11 42.3%

Which technologies does Exploramed NC7, Inc. patent most?

Top 7 of 7 technology areas

Grant record at a glance

Portfolio Volume 26 grants
CPC subclasses 7
Avg. claims / grant 12.0
Velocity -27%

Historical grant data only; it does not rate legal strength or current strategy.

Where it ranks

Overall rank by patents

#11,644

of 50,000 tracked assignees

Innovation Score

28.0 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

Where does Exploramed NC7, Inc. rank among US patent assignees?
According to USPTO PatentsView (2015–2025 granted utility patents), Exploramed NC7, Inc. ranks #11,644 of 50,000 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.
How many patents does Exploramed NC7, Inc. hold?
Exploramed NC7, Inc. holds 26 US utility patents granted between 2017 and 2020, spanning 7 technology areas.
What is Exploramed NC7, Inc.'s Innovation Score?
Exploramed NC7, Inc. has an Innovation Score of 28.0 out of 100 (top 74% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Exploramed NC7, Inc. focus on?
Exploramed NC7, Inc.'s top technology area is A61M (DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY ; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY ; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR) with 19 patents. Grants appear in 7 CPC subclasses total.
Is Exploramed NC7, Inc.'s patent grant rate increasing or decreasing?
Exploramed NC7, Inc.'s recent grant velocity is -27% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.
What does claim depth mean for Exploramed NC7, Inc.'s patents?
Exploramed NC7, Inc.'s patents average 12.0 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.
How is the Exploramed NC7, Inc. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

How to use this portfolio

Exploramed's 26 grants land it in the top 74% by Innovation Score, but volume alone doesn't tell you where the strength sits.

  • Read that count against the largest US assignees before treating it as dominance - Exploramed ranks #11,644 of 50,000. Top 50 holders
  • Most of this portfolio concentrates in A61M - see who else leads that technology area. A61M leaders
  • Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page
  • USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
  • Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
  • USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.